Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ASM JUNE 29
The Lancet - Editorial: Our Commitment to Help Accelerate Progress Against Cancer
Published:February 26, 2022
“Impressive advances in imaging, genomics, radiology, and personalised treatments have greatly improved cancer treatment, contributing to remarkable improvements in cancer survival, particularly in high-income countries. However, in low-income countries, inadequate access to essential core technologies in surgery, radiotherapy, pathology, and chemotherapy is a huge barrier to effective cancer care. To take just one example, between 2015 and 2019, the average global 5-year childhood cancer survival ranged from 11·6% in Africa to 83·0% in North America. An ethos in cancer that focuses on health systems and better care, and not just on innovation, is essential to ensure the best outcomes for all.”
DOI:https://doi.org/10.1016/S0140-6736(22)00371-3
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00371-3/fulltext
Has this been shared from May 2021? I don’t remember seeing it before. but it’s very interesting! Dr Linda Liau speaking about “DC Vacc” combos, pseudo progression, etc. One slide shows “DCVax” twice. Excellent presentation and title! Very Long NWBO!
TITLE: Immunotherapy for Glioblastoma: Overcoming Resistance with Linda M. Liau, MD, PhD, MBA;
DATE: May 19, 2021
ABOUT: Dr. Linda Liau, Professor and Chair of the Department of Neurosurgery at UCLA, presents at the Ved P. Sachdev, MD Memorial Lecture at the 2021 Mount Sinai Neurosurgery Research Day.
LINK:
Enrollment ended in 2015.
I would argue that the trial ended July 20, 2020 and was announced 4 days later on July 24th, which is their MO.
Would anyone else second this possibility? Or can anyone refute it?
In NY TIMES today:
“Her Sister Died of a Brain Tumor. Now She Was Having Similar Symptoms.”
“Humanity has planted flags on the moon, yet a moonshot for brain cancer has yet to be realized.
Forty years ago, the median survival time for glioblastoma was four-and-a-half months. Since then, researchers have characterized the genetics of glioblastoma and studied various vaccines, chemotherapies, immunotherapies, cell therapies, new imaging modalities, targeted radiation therapies and innovative forms of drug delivery to treat the disease. Many steps.
The median survival time today is about 15 months. Only a small percentage of
patients survive more than five years.”
#NakedShorts is trending top ten on Twitter - mostly related to AMC of course, but still.
Meanwhile remember Smith on Stocks has this article on NWBO:
https://smithonstocks.com/could-there-have-been-hundreds-of-millions-or-even-more-than-a-billion-counterfeit-shares-of-northwest-biotherapeutics-created-through-illegal-naked-shorting/
Very interesting.
3D concrete printing allows developers to build homes for 30% of the time and labor. Good things ahead $MDCN
— Immediate Properties (@Immediateproper) February 19, 2021
The Lancet publishes every Saturday (was visible Fri 5pm). Here’s the site.
https://www.thelancet.com/journals/lancet/home
THE LANCET ONCOLOGY publishes monthly and the Feb issue is not out yet. At the following site:
https://www.thelancet.com/journals/lanonc/home
THE NEJM publishes every Thursday and is visible every Wed 5pm here:
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_condensed
The Lancet Oncology publishes monthly. Next issue (obv): Feb 2021
The Lancet publishes weekly. Next issue: Sat Jan 30th.
Lancet Embargos for journalists/everyone last until 6:30pm the day before, from what I understand.
———-
New England Journal of Medicine (NEJM) publishes weekly.
Next issue: Thursday Feb 4th.
Embargos for journalists/everyone last until 5pm the day before, from what I understand.
The language in the last 8k makes it seem optional whether they update us on the warrants. They did so last time because they “received questions”. Perhaps they’re not obligated to do so??
11/2/20 8K:
“The Company has recently received questions concerning the status of those 233 million warrants and options and so provides the following updates:”
Flipper, didn’t the response from
SITC basically confirm for
us that NWBO will have an article in the JITC and it will be released Mon 11/9?? The question did not mention JITC. only the response did.
FROM THE SITC RESPONSE:
"...the abstract will be included in the JITC supplement that will be released on Nov. 9 at 8 a.m. EST. "
JITC: Journal of Immunotherapy of Cancer
Impact Rating > 10
Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories
Source: Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Roger M. Perlmutter will be retiring as Executive Vice President and President, Merck Research Laboratories (MRL). Dr. Perlmutter will be succeeded by Dr. Dean Y. Li, effective Jan. 1, 2021. Dr. Perlmutter will remain as a non-executive director, MRL through June 30, 2021 to facilitate a seamless transition.
“Since rejoining the company seven years ago, Dr. Roger Perlmutter has had a profound impact on Merck and the patients we exist to serve. During his tenure as its President, Merck Research Laboratories have made historic breakthroughs in immuno-oncology and other fields of medicine that have both transformed clinical practice and vastly improved patient outcomes. Roger’s legacy will include a rejuvenated research and development organization, staffed by world class scientists, clinicians and professionals and led by Dr. Dean Li. As a result of Roger’s hands-on and inspirational leadership, MRL is well positioned to bring forward lifesaving medicines and vaccines for many years to come,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “I am enormously grateful for Roger’s decision to return to Merck and for his many meaningful contributions to science, medicine and the health and wellbeing of people around the world.”
Since Roger Perlmutter’s appointment as President, Merck Research Laboratories in April 2013, the company has received more than 100 regulatory approvals for its medicines and vaccines globally. This includes more than 15 novel vaccines and therapeutics, including those for multiple cancers, diabetes, and infections caused by Ebola virus, human immunodeficiency virus, hepatitis C virus and cytomegalovirus. Most notably, under Roger’s leadership, Merck has established KEYTRUDA as a foundational immunotherapy for cancer, which continues to transform cancer care throughout the world. Since its first approval, in the U.S., KEYTRUDA has received approval for over 25 indications across 16 tumor types as well as indications for microsatellite instability-high/mismatch repair deficient and tumor mutational burden-high cancers.
“It has been an honor to lead the talented people of Merck Research Laboratories during the last seven years,” said Dr. Perlmutter. “I look forward to continuing to work with Dean over the next few months to advance our scientific strategy and continue the strong momentum in our pipeline.”
Dean Li is currently Senior Vice President of Discovery Sciences and Translational Medicine, MRL. He joined Merck in 2017 as Vice President and head of Translational Medicine. Prior to joining Merck, Dr. Li held positions of increasing responsibility in translational medical research at the University of Utah. Most recently he served as the H.A. & Edna Benning Professor of Medicine and Cardiology, Chief Scientific Officer, Associate Vice President and Vice Dean at the University of Utah Health System. During his tenure at the University of Utah, he co-founded multiple biotech companies based upon research conducted in his laboratory, including Recursion Pharmaceuticals, Hydra Biosciences and Navigen Pharmaceuticals. Dean received a bachelor’s degree from the University of Chicago and his medical degree, doctorate degree, and training in clinical medicine and cardiology at Washington University School of Medicine in St. Louis. He is a member of the American Society for Clinical Investigation and the Association of American Physicians.
“Since joining us in 2017, Dean has demonstrated strong leadership in building our discovery and translational medicine capabilities, advanced our pipeline and paved the way for Merck Research Laboratories to build on its singular legacy,” said Mr. Frazier. “Dean’s strong clinical background and deep scientific and technological expertise make him the right leader to ensure sustained execution of our broad portfolio during this important time.”
“Powerful new technologies continue to fuel important progress in enabling the discovery and development of new and better medicines and vaccines,” said Dr. Li. “I am very grateful to Roger for his mentorship and the guidance of his leadership team over the past three years and am excited by the opportunity to build upon MRL’s legacy of scientific excellence and innovation.”
About Merck
For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
View source version on businesswire.com: https://www.businesswire.com/news/home/20201002005200/en/
Media Contacts:
Pamela Eisele
(267) 305-3558
Patrick Ryan
(973) 275-7075
Investor Contacts:
Peter Dannenbaum
(908) 740-1037
Michael DeCarbo
(908) 740-1807
But RuleOfK also intimated that Senti was correct and that in his opinion DL had mostly likely NOT occurred yet.
How do you square that circle and expect TLD this week?
6:05pm today might be significant, no?
Late breaking abstracts for ESMO oral sessions get published TODAY (Thur 9/17) at 6:05pm EST. [which is 00:05 CEST on Friday, 18 September 2020.]
I don’t think this has been mentioned. Am I wrong?
“Abstracts accepted for presentation at ESMO 2020 as Proffered Paper or Mini Oral will be published online via the ESMO website at 00:05 CEST on Friday, 18 September 2020. 3. All Late-breaking abstracts will be made public at the start of the official Congress session during which they are presented.”
https://www.esmo.org/content/download/260708/5029247/1/ESMO-Congress-2020-Abstract-Submission-Regulations.pdf
Late breaking abstracts for ESMO oral sessions get published TODAY (Thur 9/17) at 6:05pm EST. [00:05 CEST on Friday, 18 September 2020.]
I don’t think this has been mentioned.
Am I wrong?
“Abstracts accepted for presentation at ESMO 2020 as Proffered Paper or Mini Oral will be published online via the ESMO website at 00:05 CEST on Friday, 18 September 2020.
3. All Late-breaking abstracts will be made public at the start of the official Congress session during which they are presented.”
https://www.esmo.org/content/download/260708/5029247/1/ESMO-Congress-2020-Abstract-Submission-Regulations.pdf
How’s my Timeline to TLD?
Thur 8/20 or Fri 8/21
Full Data Lock, data goes to statisticians.
Wed 8/26 or Thu 8/27
Announce Data Lock and Statisticians have the data - company still blinded - will take a “couple of weeks”
Tue 9/8
Company receives data/TLD from Statisticians, becomes unblinded, enters silent period, consults w boards
Mon 9/14
-Announce Company receives data/TLD from Statisticians, becomes unblinded, enters silent period, consults w boards
-ESMO virtual exhibition opens
(https://www.esmo.org/meetings/esmo-virtual-congress-2020)
Wed 9/16 - Fri 9/18
Announce TLD to the world
Or wait until....
Sat 9/19 - Mon 9/21
ESMO Virtual congress:
Bringing innovation to cancer patients. The ESMO Virtual Congress 2020 will present promising new developments aimed at improving cancer patient care. In response to the needs of the moment, the scientific programme will include a dedicated COVID-19 and cancer research track.Take part in Europe's most prestigious platform for oncology stakeholders.
https://www.esmo.org/meetings/esmo-virtual-congress-2020
I found 3 conferences in Sept 2020 that NWBO could choose for “The appropriate venue and manner of presenting the trial results” after “consulting with its principal investigator and experts” after data is “ready for reporting approximately sometime after Labor Day in the month of September.” (Quotes are from today’s 10Q)
Because the data is only “ready...after Labor Day”, we should also look at Oct/Nov conferences too, but after the company is unblinded they better get that info out quick, no? (after the statisticians do their work in “several weeks”)
So I wouldn’t think they’d wanna hold onto that unblinded info for too long.
Can anyone add to the list of upcoming conferences?
Mon 9/14 - Thur 9/17
AACR Sixth international cancer immunotherapy conference - translating science into survival
Sat 9/19 - Mon 9/21
ESMO Virtual Congress 2020
Sat 9/26
American Academy of Neurological Surgery Annual Meeting
“Accordingly, the Company is aiming to proceed with data lock at approximately the end of next week.”
MOST PERTINENT INFO FROM END OF 10Q:
“Despite these difficulties, the CRO has completed the final monitoring visits to the trial sites (including a number of them virtually), and has completed the collection of Case Report Form (CRF) data for all patients in the trial. The CRFs contain most, though not all, of the data required for analyzing the trial.
Since the Company’s prior updates, the CRO has also completed the Source Data Verification (SDV) for all of the data contained in the CRFs. Further, the CRO has completed the resolution of the many queries.
The independent service firms have also collected most of the additional data that is not contained in the CRFs, such as additional MRI scans and certain genetic information. The Company is consulting with its advisers to obtain their support for proceeding with initial data lock without waiting for these additional data, and then to include these additional data in the database when they are available.
The primary focus for reaching data lock now is obtaining the trial sites’ data locks. In order to reach overall data lock for the trial, each site’s data must be locked. Preparatory steps must be completed at each site so that the site is ready for sign-off, and then the lead investigator at the site must personally sign off on the data from that site. To that end, the lead investigator must undergo a brief training on the system, review the site data/CRFs and personally complete the confirmation and submit it.
Since the Company’s prior updates, the CRO and service firms have completed the preparatory steps for all but about ten of the sites to be ready for the investigator’s sign-off. Among the sites who had reached readiness for sign-off, about 33 sites are in varying stages of accomplishing their sign-offs and the rest of the sites have completed theirs.
The independent service firms are pressing to obtain the rest of the site completions and investigator sign-offs. The Company hopes they will be completed by approximately the end of next week. Accordingly, the Company is aiming to proceed with data lock at approximately the end of next week.
As previously reported, upon data lock the independent statisticians will be given access to the clinical trial database containing the raw data, and will undertake the applicable calculations and analyses. As previously reported, the Company will remain blinded until the statisticians have completed these calculations and analyses. That process is expected to take several weeks. The Company will then receive the initial results from the statisticians and become unblinded. Then the Company will consult with its Scientific Advisory Board, trial Steering Committee and expert advisors about the data, and address their questions and/or comments to prepare for announcement of the data.”
We are reference #38 in that link:
Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16:142. Erratum in: J Transl Med. 2018;16:179.
Top story in The NY Times right now about race to vaccine - mentions Inovio!
Here is the paragraph (link below):
“Some groups, including the American company Inovio Pharmaceuticals, are taking a totally different approach. Instead of injecting viruses or protein fragments, they’re injecting pure DNA, which is read by the cell’s machinery, making a copy as an RNA molecule. The RNA is then read by the cell’s protein-building factories, making a viral protein. The protein in turn comes out of the cell, where immune cells bump into it and make an antibody to it. Some groups, including the American company Inovio Pharmaceuticals, are taking a totally different approach. Instead of injecting viruses or protein fragments, they’re injecting pure DNA, which is read by the cell’s machinery, making a copy as an RNA molecule. The RNA is then read by the cell’s protein-building factories, making a viral protein. The protein in turn comes out of the cell, where immune cells bump into it and make an antibody to it.”
https://www.nytimes.com/2020/05/02/us/politics/vaccines-coronavirus-research.html
Wed 6/24!
NWBO ASM MTG
Sat Apr 18th
1pm EST
WEBSITE:
www.meetingcenter.io/227204437
Password:
NWBO2020
Whether you will need a “Control #” or not is unclear. Proxy says yes. Sentiment Stocks says no. (This 16-digit number can be found on your proxy voting card thru your broker)
We’ll see.
A: $6.85
B: $7.55
It seems you will also need your 16-digit CONTROL # to access the ASM on 4/18 (see proxy source* below).
The control # can be found on your proxy voting card!!!
So it seems we need 3 things for the ASM:
Website: www.meetingcenter.io/227204437
Password: NWBO2020
Control #: xxxxxxxxxxxxxxxx
Sound about right?
*SOURCE: PROXY STATEMENT
“Attending the Online Annual Meeting and Voting During the Annual Meeting:
To participate in the online Annual Meeting, registered stockholders will need the 16-digit control number included on the enclosed proxy card. The Annual Meeting will begin promptly at 1:00 p.m., Eastern Time. We encourage you to access the meeting prior to the start time to allow ample time for the check-in procedures.
1
TABLE OF CONTENTS
While the website for the meeting will have an option for voting at the time of the meeting, we ask and encourage all stockholders to vote their proxy prior to the meeting either by phone, online or proxy card.
I just don’t think this is true. In a buyout for stock, you have to consider the shares outstanding of the two companies, no?
Let’s make up a crazy scenario: Say fantastically and hypothetically - in a distant dream - completely ridiculously......Merck were to offer NWBO $40B in a buyout.
(KITE was bought for $12B and they were in phase I/II testing with a narrower market potential)
Since Merck is approximately $80/share, they need 500 million shares to accommodate for $40B ($80x500m = $40B).
(FYI: MRK currently has 2.5B shares outstanding)
Now, how do you distribute that 500 million shares to NWBO shareholders? Well, since NWBO has about a billion shares outstanding (after all warrants/options are exercised), that would mean half of a Merck share for every share of NWBO. (.5x1B= 500m)
So hypothetically under this scenario, if you owned 1000 shares in NWBO (Current Value: $250) you would now instead own 500 shares of MRK @80/share (Current Value: $40,000)
All hypothetical of course. And If I’m wrong about how all this works, Im happy to retract.
.
Another interesting date is April 24, 2020: AACR (American Association for Cancer Research), a week after the ASM.
They’ve had a presence there in the past - booths in exhibit hall - and:
2015:
https://www.biospace.com/article/releases/northwest-biotherapeutics-featured-in-presentations-at-the-aacr-annual-meeting-/
AACR: American Association for Cancer Research
San Diego Convention Center, San Diego, CA, USA
24th - 29th April, 2020
https://20meeting.org/aacr/index.php
April 18, 2020: 2019 Annual Shareholder's Meeting will be held on April 18, 2020, at 1:00 pm in Washington, DC.
Previously posted by TheFollower:
April 17,2020 - Washington Hilton, Washington DC, USA
8th Annual Symposium on Global Cancer Research
The 8th Annual Symposium on Global Cancer Research will be held on April 17, 2020, prior to the 11th Annual Consortium of Universities for Global Health (CUGH) Global Health Conference(April 18-20, 2020).
http://www.cvent.com/events/8th-annual-symposium-on-global-cancer-research-the-consortium-of-universities-for-global-health-annu/event-summary-de45e2b9e66043d0b76863f7cce55b0b.aspx?dvce=1
Let’s not forget that they supposedly already held a trial with DCVAX and KEYTRUDA combo in colorectal cancer in Germany. Announced in NOV 17, 2016!! (See below)
Does anyone have any word about that trial since?
Can’t find anything about it w basic google search.
Imagine getting this headline/PR today, after hiring Dr Duffy (who came from Merck), and after KEYTRUDA breaking sales records? Would seem great news. And yet it was over 3 years ago.
https://nwbio.com/nw-bio-announces-phase-ii-clinical-trial-program-combining-dcvax-l-and-pembrolizumab-keytruda-for-colorectal-cancer/
Interesting: NWBO is hosting a lunch and a meeting at SNO next Friday/Saturday (Page 10 of link in previous message and below):
Friday Nov 22, 2019
12:15pm - 1:15pm Northwest Biotherapeutics Patient Advocacy Group Lunch
Desert Suite I
Sat Nov 23, 2019
12:15pm - 1:15pm Northwest Biotherapeutics Nonprofit Investigator Meeting
Desert Suite I
I don't think we've seen this yet. Sorry if already mentioned.
Also saw that our booth is very centrally located in the exhibit hall! Right in the center of it all.
(Page 14 - BOOTH 214)
Go NWBO! (But anticipating more patience might be necessary - been here a while)
https://www.eventscribe.com/upload/planner/links/SNO2019MeetingProgram11819_69.pdf
It seems DCVAX might be be discussed this Saturday 11/9 at the SITC in Maryland? Robert Prins is speaking, but also check out the 6:15pm slot below by Daniela Bota, who is one of the 69 authors of our publication last year: the phase II trial she is speaking about look awfully a lot like DCVAX.And interestingly enough, one of the co-chairs is David Reardon, mentioned on the board earlier today as part of the INO pr that came out.
Probably another HUGE nothing burger, but thought Id share.
Long and strong NWBO.
-$BNYC
https://www.sitcancer.org/2019/program/annual-meeting-schedule-2019-old
Saturday, Nov. 9, 2019
Concurrent Session 311: A Tale of Two Brain Tumors: Primary versus Metastatic CNS Tumors
Time: 5:15 – 6:30 p.m.
Location: National Harbor 10-11
Co-Chairs:
Hideho Okada, MD, PhD – University of California, San Francisco
David Reardon, MD – Dana-Farber Cancer Institute
5:15 p.m.
Immunobiology of Primary CNS Tumors
Robert Prins, PhD – University of California, Los Angeles
5:35 p.m.
Immunobilogy of CNS Metastatic Tumors
Harriet M. Kluger, MD – Yale School of Medicine
5:55 p.m.
Difference Between the Application of Adoptive Cellular Therapy for Primary versus Metastatic Tumors
Richard M. Sherry, MD – National Institutes of Health
6:15 p.m.
(O22) Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma
Daniela Bota, MD, PhD – University of California Irvine
From that article it states,
“Researchers who are collaborating with the company on a phase III trial reported that 100 of the 331 people who were treated are still alive 40 months later.”
And it footnotes to the 65-author blinded publication.
But I don’t see the number “100” number anywhere in the publication. Is that number from the Bosch June presentation?
AND
Is this “still alive 40 months later”:
A) after their individual treatment?
B) after the end of the trial?
C) after last enrollment?
D) after last surgery?
E) Other
Am I talking to the wind? Perhaps.
sbnyc
$NWBO #DCVax Dr.Marnix Bosch, Chief Technical Officer, Northwest Biotherapeutics will be speaking at the Immuno-Oncology Summit in Boston, MA on Wednesday, August 29, 2018. The “Talk Title to be Announced”. See page 9: immuno-oncologysummit.com/uploadedFiles/…
"A few" in percentage terms would make some more sense. 3-4% of 331 would be 9-12 people LTFU. Not clear but perhaps not deceptive? Who knows. Just thought id chime in on that.
Or am I way off base? It happens. Often.
Marzan, the MAIN Lancet is published every Sat, BUT they release the contents of the issue online every Friday 5/6pm.
Just google Lancet and go to the journals tab, click on Lancet, then go to current issue.
Also I believe the next ASCO-type Journal is published next Thur May 10th I think (the one pub every 1st, 10th, 20th of the month)? Anyway, patience and fortitude continues for patients, doctors, and long investors.
And thank you Beartrap for all you do.
sbnyc
Actually the ASCO site says:
“APRIL 25, 2018
Full Program Available, Including Abstract Titles with iPlanner Website Launch
APRIL 25, 2018, AT 11:59 PM (EDT)
Hotel Reservations and Early Registration Deadline”
https://am.asco.org/about/dates-overview
So maybe midnight tonight?
12:00am April 25 EST?
Or maybe Chicago time?
Who knows?
sbnyc
If the vote is before the publication, then why can’t they tell us the date of the special meeting?
I’m under the assumption the publication will trigger an 8K telling us when the meeting will be?
I would love to share my predictions, but alas I won’t.
sbnyc
Well now it’s 10 months and a day since June 5, 2017.... so yeah it’s late, but if she’s off by a month, so be it? (Replying to an old message from Flipper44)
BTW The proxy mentions that physical inspection of documents is available for shareholders 10 days prior to the special meeting on April
Hi Flip. From what i googled of the Journal of Neuro-Oncology, it looks like “Volume 137, Issue 2, April 2018”
is already out.
How do you think this pub is gonna go down?
I’d be interested in placing bets on:
1) Pre-Market Release
2) Market Halt Release
3) Post-Market Release
4) Release on a Fri eve, Sat or Sun?
Also, will NWBO immediately email us when the pub is out? Will we know when it happens?
In my fantasy scenario, it happens in the Lancet, pub gets released on a Fri post-market for the Sat issue (happens every Fri), news gets digested on Saturday, the Sunday am news/talk shows are all about this new paradigm in cancer treatment. Monday market opens and insanity reigns.
Nice fantasy, eh?
All ramblings of a clueless human being, and IMO.
sbnyc
Possible Journals?
NEJM (Every Thur)
Lancet (Every Sat)
ASCO Journal (1st, 10th and 20th, so this Sunday 4/1)
Who knows?!? All just info of stuff. I’m as clueless as everyone else.
sbnyc
Haha while I’m sure this is a rhetorical question I’d love to respond to your query....
RIGHT (ALNY)
WRONG (CYGX)
MAYBE? (NWBO)
sbnyc